205171-04-6

Basic information

• Product Name: 6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine
• Synonyms: 6-CHLORO-9-(2,3,5-TRI-O-BENZOYL-2-C-METHYL-BETA-D-RIBOFURANOSYL)-9H-PURINE;6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-Methyl-β-D-ribofuranosyl)-9H-purine
• CAS NO: 205171-04-6
• Molecular Formula: C₃₂H₂₅ClN₄O₇
• Molecular Weight: 613.023
• Mol File: 205171-04-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 757.022 °C at 760 mmHg
• Flash Point: 411.632 °C
• Appearance: /
• Density: 1.41
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.667
• CAS DataBase Reference: 6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine(205171-04-6)
• EPA Substance Registry System: 6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine(205171-04-6)

Safety Data

• Hazardous Substances Data: 205171-04-6(Hazardous Substances Data)

Usage

General Description

6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine is a complex chemical compound that belongs to the class of purine nucleosides. It is composed of a purine base with a ribose sugar molecule attached. The ribose sugar is modified with three benzoyl groups and a methyl group at the 2-C position. Additionally, the purine base has a chlorine atom at the 6-position. 6-Chloro-9-(2,3,5-tri-O-benzoyl-2-C-methyl-beta-D-ribofuranosyl)-9H-purine has potential applications in medicinal chemistry and biochemistry, as it may exhibit interactions with nucleic acids and enzymes. Its intricate structure makes it a valuable target for synthetic and analytical chemistry studies.

InChI:InChI=1/C32H25ClN4O7/c1-32(44-30(40)22-15-9-4-10-16-22)25(43-29(39)21-13-7-3-8-14-21)23(17-41-28(38)20-11-5-2-6-12-20)42-31(32)37-19-36-24-26(33)34-18-35-27(24)37/h2-16,18-19,23,25,31H,17H2,1H3/t23-,25-,31-,32-/m1/s1

Upstream product

• 87-42-3 6-chloropurine 
• 15397-15-6 1,2,3,5-tetra-O-benzoyl-2-C-methyl-β-D-ribofuranose 
• 728022-71-7 2'-C-methyl-1,3,5-tribenzoylribofuranose 
• 157037-56-4 1,3,5-tri-O-benzoyl-2-oxo-α-D-erythro-pentofuranose 
• 22224-41-5 1,3,5-tri-O-benzoyl-α-D-ribofuranoside 
• 7392-74-7 (3R,4R,5R)-5-((benzoyloxy)methyl)-3-methyl-2-oxotetrahydrofuran-3,4-diyl dibenzoate 
• 98-88-4 benzoyl chloride 
• 492-30-8 2-C-methyl-D-ribono-1,4-lactone 

Downstream Products

• 15397-12-3 2'-C-methyladenosine 
• 1345970-05-9 C₃₂H₂₄N₈O₉ 
• 1345970-04-8 C₃₂H₂₄ClN₅O₉ 
• 1345970-07-1 C₃₂H₂₆ClN₅O₈ 
• 1345970-08-2 C₃₂H₂₈N₆O₈ 
• 205171-16-0 (3aR,4S,6R,6aR)-6-[6-(3-Iodo-benzylamino)-purin-9-yl]-2,2,6a-trimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid ethyl ester 
• 205171-06-8 2'-Me-CPA 
• 940280-52-4 C₃₄H₃₂N₆O₉S 

Relevant articles and documents

CYCLIC DINUCLEOTIDES AS STING AGONISTS

Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1C, R1D, B1, R2A, R2B, R2C, R2D, and R2E are defined herein and Formula (II), wherein R1H, R1K, R1J, and R2L are defined herein.

6-Hydrazinopurine 2′-methyl ribonucleosides and their 5′-monophosphate prodrugs as potent hepatitis C virus inhibitors

A series of 6-hydrazinopurine 2′-methyl ribonucleosides was synthesized and tested for its inhibitory activity against the hepatitis C virus (HCV). The lack of antiviral activity of these nucleosides was associated with a poor affinity for adenosine kinase, which prompted us to synthesize several of their 5′-monophosphate prodrugs. Some of these prodrugs exhibited more than 1000-fold improvement in anti-HCV activity when compared to their parent nucleosides (EC50 of 24 nM vs 92 μM for the parent).

Synthesis of 9-(2-β-C-methyl-β-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication

A series of 9-(2′-β-C-methyl-β-d-ribofuranosyl)-6- substituted purine derivatives were synthesized as potential inhibitors of HCV RNA replication. Their inhibitory activities in a cell based HCV replicon assay were reported. A prodrug approach was used to